Wrighton S A, Stevens J C, Becker G W, VandenBranden M
Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285.
Arch Biochem Biophys. 1993 Oct;306(1):240-5. doi: 10.1006/abbi.1993.1506.
In an effort to identify and characterize minor forms of human liver cytochrome P450, immunoblot analyses of microsome samples were developed with antibodies to various P450s that recognized multiple human P450s. Four P450s were recognized in immunoblot analyses of human liver microsome samples developed with an antibody previously demonstrated to specifically recognize rat 2B1/2. Three of these P450s were identified as 2A6, 2C9/10, and 2E1 and the fourth was termed P450UK. A monoclonal antibody to 2C9/10 recognized P450UK in addition to 2C9/10. In order to identify P450UK, it was purified and subjected to amino-terminal amino acid analysis. The amino-terminal sequence obtained for P450UK was identical to the sequence deduced from a cDNA encoding CYP2C19, thus identifying P450UK as 2C19. The relative levels of 2C19 were determined in 14 human liver microsome samples by quantitative immunoblot analyses developed with the anti-2C9/10 antibody. These analyses demonstrated that 2C19 was not detected in one sample and its levels varied 10.5-fold in the remaining samples. The levels of 2C19 were compared to the relative levels and catalytic activities of multiple human liver P450s. The levels of 2C19 and the ability of the samples to 4'-hydroxylate S-mephenytoin were found to strongly correlate (r2 = 0.79). In summary, this is the first demonstration of the expression of 2C19 at the enzyme level, and the correlation studies suggest that 2C19 plays a role in the 4'-hydroxylation of S-mephenytoin.
为了鉴定和表征人类肝脏细胞色素P450的次要形式,利用识别多种人类P450的针对各种P450的抗体,开展了微粒体样品的免疫印迹分析。在用先前证明能特异性识别大鼠2B1/2的抗体开展的人类肝脏微粒体样品免疫印迹分析中,识别出了四种P450。其中三种P450被鉴定为2A6、2C9/10和2E1,第四种被称为P450UK。一种针对2C9/10的单克隆抗体除了识别2C9/10外,还识别P450UK。为了鉴定P450UK,对其进行了纯化并进行了氨基末端氨基酸分析。获得的P450UK的氨基末端序列与从编码CYP2C19的cDNA推导的序列相同,从而将P450UK鉴定为2C19。通过用抗2C9/10抗体开展的定量免疫印迹分析,测定了14份人类肝脏微粒体样品中2C19的相对水平。这些分析表明,在一个样品中未检测到2C19,其水平在其余样品中变化了10.5倍。将2C19的水平与多种人类肝脏P450的相对水平和催化活性进行了比较。发现2C19的水平与样品使S-美芬妥因4'-羟化的能力密切相关(r2 = 0.79)。总之,这是首次在酶水平上证明2C19的表达,相关性研究表明2C19在S-美芬妥因的4'-羟化中起作用。